

ACADIA PHARMACEUTICALS INC  
Form SC 13G/A  
October 21, 2009

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**SCHEDULE 13G/A**

**Under the Securities Exchange Act of 1934  
(Amendment No. 2)**

**Acadia Pharmaceuticals Inc.**

(Name of Issuer)

**Common Stock**

(Title of Class of Securities)

**0042251084**

(CUSIP Number)

**October 14, 2009**

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)
- Rule 13d-1(c)
- Rule 13d-1(d)

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 ( Act ) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Edgar Filing: ACADIA PHARMACEUTICALS INC - Form SC 13G/A

CUSIP No. 0042251084

1 Name of Reporting Person  
Sepracor Inc.

S.S. or I.R.S. Identification No. of Above Person

22-2536587

2 Check the Appropriate Box if a Member of a Group

(a)   
(b)

3 SEC Use Only

4 Citizenship or Place of Organization  
Delaware

|   |   |                                     |
|---|---|-------------------------------------|
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Reporting<br>Person With | 5 | Sole Voting Power<br>1,890,422      |
|   | 6 | Shared Voting Power<br>0            |
|   | 7 | Sole Dispositive Power<br>1,890,422 |
|   | 8 | Shared Dispositive Power<br>0       |

9 Aggregate Amount Beneficially Owned by Reporting Person  
1,890,422

10 Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares

11 Percent of Class Represented by Amount in Row (9)  
5.1%

12 Type of Reporting Person  
CO

Edgar Filing: ACADIA PHARMACEUTICALS INC - Form SC 13G/A

CUSIP No. 0042251084

1 Name of Reporting Person  
Dainippon Sumitomo Pharma America Holdings, Inc.

S.S. or I.R.S. Identification No. of Above Person

27-0534130

2 Check the Appropriate Box if a Member of a Group

(a)   
(b)

3 SEC Use Only

4 Citizenship or Place of Organization  
Delaware

|   |   |                                     |
|---|---|-------------------------------------|
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Reporting<br>Person With | 5 | Sole Voting Power<br>1,890,422      |
|   | 6 | Shared Voting Power<br>0            |
|   | 7 | Sole Dispositive Power<br>1,890,422 |
|   | 8 | Shared Dispositive Power<br>0       |

9 Aggregate Amount Beneficially Owned by Reporting Person  
1,890,422

10 Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares

11 Percent of Class Represented by Amount in Row (9)  
5.1%

12 Type of Reporting Person  
CO

Edgar Filing: ACADIA PHARMACEUTICALS INC - Form SC 13G/A

CUSIP No. 0042251084

1 Name of Reporting Person  
Dainippon Sumitomo Pharma Co. Ltd.

S.S. or I.R.S. Identification No. of Above Person

Not Applicable

2 Check the Appropriate Box if a Member of a Group  
(a)   
(b)

3 SEC Use Only

4 Citizenship or Place of Organization  
Osaka, Japan

|   |   |                                     |
|---|---|-------------------------------------|
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Reporting<br>Person With | 5 | Sole Voting Power<br>1,890,422      |
|   | 6 | Shared Voting Power<br>0            |
|   | 7 | Sole Dispositive Power<br>1,890,422 |
|   | 8 | Shared Dispositive Power<br>0       |

9 Aggregate Amount Beneficially Owned by Reporting Person  
1,890,422

10 Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares

11 Percent of Class Represented by Amount in Row (9)  
5.1 %

12 Type of Reporting Person  
CO

**Amendment No. 2 to Schedule 13G**

This Amendment No. 2 to Schedule 13G amends and restates in its entirety the Schedule 13G originally filed on January 20, 2005, as amended on February 6, 2007, by Sepracor Inc. ( Sepracor ). This Amendment No. 2 is being filed to report additional beneficial owners of BioSphere Medical, Inc. common stock resulting from the acquisition of a majority ownership interest in Sepracor by Dainippon Sumitomo Pharma Co., Ltd. ( DSP ). On September 15, 2009, pursuant to the Agreement and Plan of Merger, dated as of September 3, 2009, by and among Sepracor, DSP and Aptiom, Inc. ( Aptiom ), a direct wholly-owned subsidiary of Dainippon Sumitomo Pharma America Holdings, Inc. ( DSPAH ) and an indirect wholly-owned subsidiary of DSP, DSP and Aptiom commenced a tender offer (the Offer ) to acquire all of the outstanding shares of common stock of Sepracor. The initial offering period of the Offer expired at 12:00 Midnight, New York City time, at the end of the day on Tuesday, October 13, 2009, and Aptiom accepted for payment all shares of Sepracor common stock that were validly tendered and not properly withdrawn in the Offer as of that time. As a result of such acceptance, Aptiom, as well as, DSPAH and DSP, through their direct and indirect ownership of Aptiom, respectively, acquired a majority ownership interest in Sepracor. On October 20, 2009 Aptiom merged with and into Sepracor, and Sepracor became a direct wholly-owned subsidiary of DSPAH and an indirect wholly-owned subsidiary of DSP.

**Item 1**

- (a) Name of Issuer
- (b) Acadia Pharmaceuticals Inc. (the Issuer )  
Address of Issuer s Principal Executive Office
- 3911 Sorrento Valley Boulevard
- San Diego, CA 92121

**Item 2**

- (a) Names of Persons Filing
- This Statement is being filed on behalf of each of the following persons collectively, the Reporting Persons ):
- (i) Sepracor Inc.
- (ii) Dainippon Sumitomo Pharma America Holdings, Inc.
- (iii) Dainippon Sumitomo Pharma Co., Ltd.
- (b) Address of Principal Business Office

The address of the principal business offices of the Reporting Persons is:

Sepracor Inc.  
94 Waterford Drive

Edgar Filing: ACADIA PHARMACEUTICALS INC - Form SC 13G/A

Marlborough, MA 01752

Dainippon Sumitomo Pharma America Holdings, Inc.  
One Bridge Plaza, Suite 510  
Fort Lee, New Jersey 07024

Dainippon Sumitomo Pharma Co., Ltd.  
6-8 Doshomachi 2-Chrome  
Chu-Ku, Osaka 541-0045  
Japan

(c) Citizenship

(i) a Delaware corporation

(ii) a Delaware corporation

(iii) organized under the laws of Japan

(d) Title of Class of Securities

Common Stock, par value \$0.0001 per share (the Common Stock )

(e) CUSIP Number

0042251084

**Item 3** This statement is not being filed pursuant to either Rule 13d-1(b) or 13d-2(b) or (c).

CUSIP No. 0042251084

**Item 4 Ownership**

- (a) Amount Beneficially owned:  
1,890,422 shares of Common Stock
- (b) Percent of class:  
5.1%
- (c) Number of Shares as to which each of the Reporting Persons has:
  - (i) Sole power to vote or to direct the vote
  - (ii) 1,890,422 shares of Common Stock  
Shared power to vote or to direct the vote
  - (iii) 0 shares  
Sole power to dispose or direct the disposition of
  - (iv) 1,890,422 shares of Common Stock  
Shared power to dispose or to direct the disposition of  
0 shares

**Item 5 Ownership of Five Percent or Less of a Class**

If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owners of more than five percent of the class of securities, check the following o.

**Item 6 Ownership of More than Five Percent on Behalf of Another Person**

Not applicable.

**Item 7 Identification and Classification of Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person**

Not applicable

**Item 8 Identification and Classification of Members of the Group**

Not applicable

**Item 9 Notice of Dissolution of Group**

Not applicable.

**Item 10 Certification**

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

**SIGNATURES**

In accordance with Rule 13(d)-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing with each other of the attached statement on Schedule 13G and to all amendments to such statement. After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: October 21, 2009

SEPRACOR INC.

By: /s/ Robert Scumaci  
Name: Robert Scumaci  
Title: CFO

Dated: October 21, 2009

DAINIPPON SUMITOMO PHARMA AMERICA HOLDINGS, INC.

By: /s/ Nobuhiko Tamura  
Name: Nobuhiko Tamura  
Title: President

Dated: October 21, 2009

DAINIPPON SUMITOMO PHARMA CO., LTD.

By: /s/ Yutaka Takeuchi  
Name: Yutaka Takeuchi  
Title: Member, Board of Directors,  
and Executive Officer